Mark H. Schoenfisch

Add links
From Wikipedia, the free encyclopedia
Mark H. Schoenfisch
Born
Elgin, Illinois
NationalityAmerican
Alma materUniversity of Kansas (B.A., 1992)
University of Arizona (Ph.D., 1997)
Scientific career
FieldsChemistry
InstitutionsUniversity of North Carolina at Chapel Hill
Doctoral advisorJeanne E. Pemberton

Mark H. Schoenfisch (/ˈʃeɪnfɪʃ/ SHANE-fish) is an American analytical chemist. He is the Peter A. Ornstein Distinguished Professor of Chemistry at the University of North Carolina at Chapel Hill and is jointly appointed with the institution's Schools of Medicine and Pharmacy.[1] His research interests include analytical sensors, biomaterials, and the development of macromolecular nitric oxide release scaffolds as novel therapeutics. Intellectual property originating from his research group is the basis of technology being commercialized by Novan, Diabetic Health, and Vast Therapeutics located in the Research Triangle Park.[2]

Early life and education[edit]

Mark H. Schoenfisch was born in Elgin, Illinois. He attended William Fremd High School in Palatine, Illinois (class of 1988) and graduated from the University of Kansas in 1992 with a B.A. in Chemistry and Germanic Languages & Literature. Schoenfisch went on to receive his Ph.D. in Chemistry at the University of Arizona in 1997.

Career[edit]

In 1998, Schoenfisch worked as a NIH Postdoctoral Fellow under the Department of Chemistry at the University of Michigan. He moved to Chapel Hill, North Carolina, and began his independent research career as an Assistant Professor of Chemistry at the University of North Carolina at Chapel Hill in 2000. He was promoted to Associate Professor in 2005, and Full Professor in 2009. He was appointed as Peter A. Ornstein Distinguished Professor in 2018.

Research[edit]

The Schoenfisch group works at the interface analytical chemistry, materials science, biomedical engineering, and pharmacology. Research within the Schoenfisch group is currently focused on four main areas:[2]

  1. Designing macromolecular nitric oxide release vehicles as novel therapeutics for treating disease[3]
  2. Improving the analytical performance of implantable continuous glucose monitoring devices for diabetes management[citation needed]
  3. Designing microfluidic nitric oxide (NO) sensors for real-time detection of NO in biological media[4]
  4. Developing superhydrophobic interfaces for mold prevention and remediation

Awards and honors[edit]

In 1998, Schoenfisch received the National Institutes of Health Postdoctoral Fellowship.[5] He received the Society for Analytical Chemists of Pittsburgh Young Investigator Award in 2001, the Eli Lilly and Company Young Investigator Award in 2002, the National Science Foundation CAREER Award in 2004 and the International Union of Pure and Applied Chemistry Young Observer Award in 2005.[1][6][7] Schoenfisch was recognized as a prominent professor in 2007 when he received the John L. Sanders Award for Distinguished Undergraduate Teaching and Service.[8] In 2015, he received both the Chapman Family Teaching Award for Distinguished Teaching of Undergraduates as well as the Institute for the Arts and Humanities Faculty Fellowship.[9][10] In 2018, he received UNC's Office of Commercialization and Economic Development Inventor of the Year Award.[11]

Commercialization interests[edit]

Schoenfisch is a cofounder of Novan, Inc. (2006). The public pharmaceutical company focuses primarily on the development of nitric oxide release-based therapies for dermatological indications. One lead product is an anti-acne drug, which has completed Phase 3 clinical trial.[12] At least three other drugs are being developed, including topical anti-virals for the treatment of molluscum contagiosum (Phase 3) and external genital warts caused by the human papillomavirus (Phase 2), and a topical for the treatment of onychomycosis (Phase 2).[13]

Schoenfisch is also a cofounder of KnowBIO, LLC and Vast Therapeutics, Inc., 2017. Vast focuses on the development of water-soluble nitric oxide-releasing biopolymers for treating chronic respiratory infections.[14]

References[edit]

  1. ^ a b "Department of Chemistry Mark Schoenfisch". University of North Carolina at Chapel Hill. Archived from the original on 2014-02-23. Retrieved 2018-03-20.
  2. ^ a b "Schoenfisch Lab". Schoenfisch Lab. Retrieved 2018-03-20.
  3. ^ "Potential CF Therapy for Bacterial Infections Gets Patent, May Start Clinical Testing". Cystic Fibrosis News Today. 2018-01-10. Retrieved 2018-04-27.
  4. ^ "Xconomy: Biotech Startups at UNC Showcase Target Urgent Medical Needs". Xconomy. 2017-04-21. Retrieved 2018-04-27.
  5. ^ Coneski, Peter N.; Schoenfisch, Mark H. (2012-05-21). "Nitric Oxide Release Part III. Measurement and Reporting". Chemical Society Reviews. 41 (10): 3753–3758. doi:10.1039/c2cs15271a. PMC 3341472. PMID 22362308.
  6. ^ "NSF Award Search: Award#0349091 – CAREER: Molecular Imaging of Protein Adsorption with Immunoassay-Atomic Force Microscopy". www.nsf.gov. Retrieved 2018-04-27.
  7. ^ "43rd IUPAC Meeting Agenda Book" (PDF).
  8. ^ "22 Across Campus Recognized With Teaching Awards – UNC General Alumni Association". alumni.unc.edu. Retrieved 2018-04-27.
  9. ^ "Previous Winners of the Chapman Family Teaching Awards – Executive Vice Chancellor & Provost – UNC Chapel Hill". Executive Vice Chancellor & Provost – UNC Chapel Hill. 2018-02-02. Retrieved 2018-04-27.
  10. ^ "IAH Welcomes 2015–2016 Cohort of Faculty Fellows – INSTITUTE for the ARTS & HUMANITIES". INSTITUTE for the ARTS & HUMANITIES. 2015-08-12. Retrieved 2018-04-27.
  11. ^ "Carolina Innovations Seminar | Office of Commercialization and Economic Development". oced.unc.edu. Retrieved 2018-04-27.
  12. ^ "Novan Therapeutics :: Novan Announces Positive Phase 2 Results for Novel Acne Treatment". www.novan.comaccess-date=2018-04-24.
  13. ^ "Novan – SB208". www.novan.com. Retrieved 2018-04-24.
  14. ^ "Home". Vast Therapeutics, Inc. Retrieved 2018-04-24.

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Mark_H._Schoenfisch&oldid=1176280058"